NNI-351

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameNNI-351
Drug Alias NameNNI-351
ClassificationSmall molecules
Mechanisms of ActionNerve growth factor stimulantsDYRK kinase inhibitors
TargetsDYRK kinaseNerve growth factor
Therapy Area/IndicationsStress Disorders, Post-TraumaticAttention Deficit Disorder with HyperactivityFragile X Syndrome +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNeuronascent Inc
China Registration ClassN/A

Develop Information

Active CompaniesNeuronascent Inc
Inactive CompaniesN/A
Active IndicationsStress Disorders, Post-TraumaticAttention Deficit Disorder with HyperactivityFragile X Syndrome +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A